Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives
- PMID: 20509970
- PMCID: PMC2890610
- DOI: 10.1186/1476-4598-9-131
Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives
Abstract
Background: A maximum entropy approach is proposed to predict the cytotoxic effects of a panel of colchicine derivatives in several human cancer cell lines. Data was obtained from cytotoxicity assays performed with 21 drug molecules from the same family of colchicine compounds and correlate these results with independent tubulin isoform expression measurements for several cancer cell lines. The maximum entropy method is then used in conjunction with computed relative binding energy values for each of the drug molecules against tubulin isotypes to which these compounds bind with different affinities.
Results: We have found by using our analysis that alphabetaI and alphabetaIII tubulin isoforms are the most important isoforms in establishing predictive response of cancer cell sensitivity to colchicine derivatives. However, since alphabetaI tubulin is widely distributed in the human body, targeting it would lead to severe adverse side effects. Consequently, we have identified tubulin isotype alphabetaIII as the most important molecular target for inhibition of microtubule polymerization and hence cancer cell cytotoxicity. Tubulin isotypes alphabetaI and alphabetaII are concluded to be secondary targets.
Conclusions: The benefit of being able to correlate expression levels of specific tubulin isotypes and the resultant cell death effect is that it will enable us to better understand the origin of drug resistance and hence design optimal structures for the elimination of cancer cells. The conclusion of the study described herein identifies tubulin isotype alphabetaIII as a target for optimized chemotherapy drug design.
Figures









Similar articles
-
Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.PLoS One. 2016 May 26;11(5):e0156048. doi: 10.1371/journal.pone.0156048. eCollection 2016. PLoS One. 2016. PMID: 27227832 Free PMC article.
-
Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids.J Comput Aided Mol Des. 2014 Jul;28(7):751-63. doi: 10.1007/s10822-014-9756-9. Epub 2014 Jun 11. J Comput Aided Mol Des. 2014. PMID: 24916062
-
Design and discovery of new antiproliferative 1,2,4-triazin-3(2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site.Bioorg Chem. 2021 Jul;112:104965. doi: 10.1016/j.bioorg.2021.104965. Epub 2021 May 5. Bioorg Chem. 2021. PMID: 34020238
-
Novel Colchicine Derivatives and their Anti-cancer Activity.Curr Top Med Chem. 2017;17(22):2538-2558. doi: 10.2174/1568026617666170104143618. Curr Top Med Chem. 2017. PMID: 28056740 Review.
-
Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.Curr Top Med Chem. 2019;19(15):1289-1304. doi: 10.2174/1568026619666190618130008. Curr Top Med Chem. 2019. PMID: 31210108 Review.
Cited by
-
Tubulin-interactive stilbene derivatives as anticancer agents.Cell Mol Biol Lett. 2013 Sep;18(3):368-97. doi: 10.2478/s11658-013-0094-z. Epub 2013 Jul 1. Cell Mol Biol Lett. 2013. PMID: 23818224 Free PMC article. Review.
-
6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.Cancer Chemother Pharmacol. 2019 Feb;83(2):237-254. doi: 10.1007/s00280-018-3726-1. Epub 2018 Nov 13. Cancer Chemother Pharmacol. 2019. PMID: 30426158 Free PMC article.
-
βIII-tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c-Met positive non-small cell lung cancer cells.Cancer Med. 2023 Feb;12(4):4455-4471. doi: 10.1002/cam4.5128. Epub 2022 Aug 10. Cancer Med. 2023. PMID: 35946957 Free PMC article.
-
In silico Investigations of the Mode of Action of Novel Colchicine Derivatives Targeting β-Tubulin Isotypes: A Search for a Selective and Specific β-III Tubulin Ligand.Front Chem. 2020 Feb 21;8:108. doi: 10.3389/fchem.2020.00108. eCollection 2020. Front Chem. 2020. PMID: 32154219 Free PMC article.
-
Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.PLoS One. 2010 Sep 3;5(9):e12564. doi: 10.1371/journal.pone.0012564. PLoS One. 2010. PMID: 20838440 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources